Risk factors for discontinuing intravenous patient-controlled analgesia after thoracic surgery.

IF 2.1 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Annals of Thoracic Medicine Pub Date : 2024-01-01 Epub Date: 2024-01-25 DOI:10.4103/atm.atm_159_23
Saeyeon Kim, Beatrice Chia-Hui Shih, In-Ae Song, Tak Kyu Oh
{"title":"Risk factors for discontinuing intravenous patient-controlled analgesia after thoracic surgery.","authors":"Saeyeon Kim, Beatrice Chia-Hui Shih, In-Ae Song, Tak Kyu Oh","doi":"10.4103/atm.atm_159_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study examined the risk factors of experiencing side effects from using intravenous patient-controlled analgesia (IV PCA) following lung and esophageal surgery.</p><p><strong>Methods: </strong>Our study included adult patients who underwent lung or esophageal surgery and received IV PCA for postoperative acute pain control between 2020 and 2022. We collected information on side effects from IV PCA use, the decision to discontinue PCA, and the PCA regimen from the daily reports of the acute pain management team and verified the accuracy using electronic records from ward nurses. The primary outcome was the risk factor associated with discontinuing IV PCA due to its side effects.</p><p><strong>Results: </strong>Out of the 1796 patients in our study, 1795 used PCA containing opioids; 196 patients stopped IV PCA due to unbearable side effects. Being female (adjusted odds ratio [aOR]: 2.65, 95% confidence interval [CI]: 1.70, 4.13) was linked to a higher chance of stopping PCA use. Having hypertension (aOR: 0.46, 95% CI: 0.26, 0.81) and being classified as the American Society of Anesthesiologists class 3 or higher (aOR: 0.48, 95% CI: 0.23, 0.86) were associated with a lower chance of discontinuing PCA use.</p><p><strong>Conclusion: </strong>Our study determined the risk factors to stop using IV PCA due to side effects following lung or esophageal surgery. These results emphasize the need for personalized pain management plans that take into account the patient's characteristics and the type of surgery performed.</p>","PeriodicalId":50760,"journal":{"name":"Annals of Thoracic Medicine","volume":"19 1","pages":"81-86"},"PeriodicalIF":2.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911240/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Thoracic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/atm.atm_159_23","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This study examined the risk factors of experiencing side effects from using intravenous patient-controlled analgesia (IV PCA) following lung and esophageal surgery.

Methods: Our study included adult patients who underwent lung or esophageal surgery and received IV PCA for postoperative acute pain control between 2020 and 2022. We collected information on side effects from IV PCA use, the decision to discontinue PCA, and the PCA regimen from the daily reports of the acute pain management team and verified the accuracy using electronic records from ward nurses. The primary outcome was the risk factor associated with discontinuing IV PCA due to its side effects.

Results: Out of the 1796 patients in our study, 1795 used PCA containing opioids; 196 patients stopped IV PCA due to unbearable side effects. Being female (adjusted odds ratio [aOR]: 2.65, 95% confidence interval [CI]: 1.70, 4.13) was linked to a higher chance of stopping PCA use. Having hypertension (aOR: 0.46, 95% CI: 0.26, 0.81) and being classified as the American Society of Anesthesiologists class 3 or higher (aOR: 0.48, 95% CI: 0.23, 0.86) were associated with a lower chance of discontinuing PCA use.

Conclusion: Our study determined the risk factors to stop using IV PCA due to side effects following lung or esophageal surgery. These results emphasize the need for personalized pain management plans that take into account the patient's characteristics and the type of surgery performed.

胸外科手术后停止静脉注射患者自控镇痛剂的风险因素。
目的:本研究探讨了肺部和食管手术后使用静脉患者自控镇痛(IVA)出现副作用的风险因素:我们的研究纳入了 2020 年至 2022 年间接受肺部或食管手术并接受静脉 PCA 术后急性疼痛控制的成年患者。我们从急性疼痛管理小组的每日报告中收集了有关静脉 PCA 副作用、停止 PCA 的决定以及 PCA 方案的信息,并通过病房护士的电子记录核实了信息的准确性。主要结果是因副作用而停止使用静脉 PCA 的相关风险因素:在我们的研究中,1796 名患者中有 1795 人使用了含有阿片类药物的 PCA;196 名患者因无法忍受副作用而停止了静脉 PCA。女性(调整后的几率比 [aOR]:2.65,95% 置信区间 [CI]:1.70, 4.13)与停止使用 PCA 的几率较高有关。高血压(aOR:0.46,95% CI:0.26,0.81)和美国麻醉医师协会 3 级或以上(aOR:0.48,95% CI:0.23,0.86)与停用 PCA 的几率较低有关:我们的研究确定了肺部或食道手术后因副作用而停止使用静脉 PCA 的风险因素。这些结果表明,需要根据患者的特点和手术类型制定个性化的疼痛治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Thoracic Medicine
Annals of Thoracic Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-RESPIRATORY SYSTEM
CiteScore
4.10
自引率
4.30%
发文量
19
审稿时长
>12 weeks
期刊介绍: The journal will cover studies related to multidisciplinary specialties of chest medicine, such as adult and pediatrics pulmonology, thoracic surgery, critical care medicine, respiratory care, transplantation, sleep medicine, related basic medical sciences, and more. The journal also features basic science, special reports, case reports, board review , and more. Editorials and communications to the editor that explore controversial issues and encourage further discussion by physicians dealing with chest medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信